. Author manuscript; available in PMC: 2018 Dec 20.

Published in final edited form as: Cancer Chemother Pharmacol. 2015 Mar 5;75(5):923–928. doi: 10.1007/s00280-015-2711-1

Table 1.

Perifosine pharmacokinetic parameters for plasma (a) and cerebrospinal fluid (b)

NHP	C_max (µg/ml)	T_max (h)^*	AUC (µg h/ml)	T _1/2 (h)	Cl (ml/h)
a
1	7.1	19	1431	221	77.6
2	8.8	19	2139	193	36.5
3	5.3	19	1137	170	63.3
Mean	7.1	19	1569	195	59.1
SD	1.7		514	25.2	20.9

NHP	C_max (ng/ml)	T_max (h)	AUC (ng h/ml)	t _1/2 (h)	AUC_CSF:AUC_Pl

b
1	1.85	63.6	1031	146	.0007
2	4.39	235.3	3440	277	.0016
3	4.57	235.4	2890	350	.0025
Mean	3.60	178.1	2454	258	.0016
SD	1.52	99	1262	103	.0009

C_max Maximum concentration measured, T_max time of maximum concentration after oral dose, AUC area under the concentration × time curve from T = 0 to infinity, t_½, terminal half-life; Cl, Clearance; AUC_CSF:AUC_Pl, ratio of the AUC _0−inf for CSF/AUC _0−inf for plasma

First time point following oral dose of perifosine

Table 1.

Table 1.